95233-18-4 | Atovaquone

Packsize	Purity	Availability	Price	Discounted Price
250mg	98%	in stock	$23.00	$16.00
1g	98%	in stock	$60.00	$42.00
5g	98%	in stock	$220.00	$154.00
25g	98%	in stock	$726.00	$508.00

Description

• Catalog Number: AB48646
• Chemical Name: Atovaquone
• CAS Number: 95233-18-4
• Molecular Formula: C22H19ClO3
• Molecular Weight: 366.8375
• MDL Number: MFCD00889188
• SMILES: Clc1ccc(cc1)[C@@H]1CC[C@H](CC1)C1=C(O)C(=O)c2c(C1=O)cccc2
• NSC Number: 759582

Computed Properties

• Complexity: 595
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 2
• XLogP3: 5.2

Literature

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP).

  Journal of medicinal chemistry 20140327

• In vitro and in vivo combination of cepharanthine with anti-malarial drugs.

  Malaria journal 20140101

• Design, synthesis and biological evaluation of WC-9 analogs as antiparasitic agents.

  European journal of medicinal chemistry 20131101

• FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.

  Chemico-biological interactions 20130905

• Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.

  Journal of medicinal chemistry 20130613

• The antimalarial activities of methylene blue and the 1,4-naphthoquinone 3-[4-(trifluoromethyl)benzyl]-menadione are not due to inhibition of the mitochondrial electron transport chain.

  Antimicrobial agents and chemotherapy 20130501

• On dihydroorotate dehydrogenases and their inhibitors and uses.

  Journal of medicinal chemistry 20130425

• Quinolone-3-diarylethers: a new class of antimalarial drug.

  Science translational medicine 20130320

• 4(1H)-Quinolones with liver stage activity against Plasmodium berghei.

  Antimicrobial agents and chemotherapy 20130101

• A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.

  Malaria journal 20130101

• Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design.

  Proceedings of the National Academy of Sciences of the United States of America 20121226

• New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.

  Experimental parasitology 20121201

• Efficacy and safety of atovaquone-proguanil in treating imported malaria in Japan: the second report from the research group.

  Parasitology international 20120901

• A cluster of Plasmodium vivax malaria in an expedition group to Ethiopia: prophylactic efficacy of atovaquone/proguanil on liver stages of P. vivax.

  The Journal of infection 20120901

• Re-emergence of Babesia conradae and effective treatment of infected dogs with atovaquone and azithromycin.

  Veterinary parasitology 20120608

• Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.

  Journal of medicinal chemistry 20120510

• Characterization of Plasmodium liver stage inhibition by halofuginone.

  ChemMedChem 20120501

• Standby emergency treatment of malaria in travelers: experience to date and new developments.

  Expert review of anti-infective therapy 20120501

• Development of in vitro atovaquone-resistant Babesia gibsoni with a single-nucleotide polymorphism in cytb.

  Veterinary parasitology 20120430

• Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug.

  The Journal of infectious diseases 20120415

• Dosing rationale for fixed-dose combinations in children: shooting from the hip?

  Clinical pharmacology and therapeutics 20120401

• Bridging strategies for drug combinations in pediatric indications.

  Clinical pharmacology and therapeutics 20120401

• Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression.

  The Journal of biological chemistry 20120323

• Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).

  Journal of medicinal chemistry 20120308

• Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).

  Journal of medicinal chemistry 20120308

• Anti-malarial chemoprophylaxis following evacuation from Afghanistan.

  Journal of the Royal Army Medical Corps 20120301

• Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120115

• Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.

  The American journal of tropical medicine and hygiene 20120101

• Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation.

  Clinical transplantation 20120101

• The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum.

  Malaria journal 20120101

• Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study.

  Malaria journal 20120101

• A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria.

  PloS one 20120101

• Atovaquone ameliorate gastrointestinal toxoplasmosis complications in a pregnancy model.

  Medical science monitor : international medical journal of experimental and clinical research 20120101

• [Mitochondria as targets of chemotherapy].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20120101

• Focused Screening and Treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia.

  PloS one 20120101

• Identification and validation of tetracyclic benzothiazepines as Plasmodium falciparum cytochrome bc1 inhibitors.

  Chemistry & biology 20111223

• Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.

  Journal of medicinal chemistry 20111222

• Cyclodextrin/poly(anhydride) nanoparticles as drug carriers for the oral delivery of atovaquone.

  Biomedical microdevices 20111201

• Review: Malaria chemoprophylaxis for travelers to Latin America.

  The American journal of tropical medicine and hygiene 20111201

• Malaria therapy in HIV: drug interactions between nevirapine and quinine.

  International journal of STD & AIDS 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• [Atovaquone-proguanil treatment failure in Plasmodium falciparum].

  Presse medicale (Paris, France : 1983) 20111101

• Pharmacokinetics of antimalarials in pregnancy: a systematic review.

  Clinical pharmacokinetics 20111101

• Prophylactic use of antimalarials during pregnancy.

  Canadian family physician Medecin de famille canadien 20111101

• Synthetic chromanol derivatives and their interaction with complex III in mitochondria from bovine, yeast, and Leishmania.

  Chemical research in toxicology 20111017

• Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand.

  Wiener klinische Wochenschrift 20111001

• Variation among Plasmodium falciparum strains in their reliance on mitochondrial electron transport chain function.

  Eukaryotic cell 20110801

• Synthesis and biological activities of 4-N-(anilinyl-n-[oxazolyl])-7-chloroquinolines (n=3' or 4') against Plasmodium falciparum in in vitro models.

  Bioorganic & medicinal chemistry letters 20110801

• [Diagnosis and treatment of pneumocystis jirovecii pneumonia].

  Deutsche medizinische Wochenschrift (1946) 20110701

• Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.

  Journal of medicinal chemistry 20110609

• Community management of anti-malarials in Africa and iatrogenic risk.

  Journal of tropical pediatrics 20110601

• Persistent babesiosis in a stem cell transplant recipient.

  Leukemia research 20110601

• Diagnostic and therapeutic challenges.

  Retina (Philadelphia, Pa.) 20110601

• Yeast dihydroorotate dehydrogenase as a new selectable marker for Plasmodium falciparum transfection.

  Molecular and biochemical parasitology 20110501

• Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.

  Antimicrobial agents and chemotherapy 20110401

• Babesiosis in an Egyptian boy aquired from pet dog, and a general review.

  Journal of the Egyptian Society of Parasitology 20110401

• Azithromycin for treating uncomplicated malaria.

  The Cochrane database of systematic reviews 20110216

• Atovaquone-proguanil use in early pregnancy and the risk of birth defects.

  Archives of internal medicine 20110214

• SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.

  Journal of drug targeting 20110201

• Plasmodium falciparum: Solanum nudum SN-1 steroid antiplasmodial activity when combined with antimalarial drugs.

  Experimental parasitology 20110101

• [Post-malaria neurological syndrome complicating a relapse of Plasmodium falciparum malaria after atovaquone-proguanil treatment].

  Medecine et maladies infectieuses 20110101

• Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review.

  Transplant international : official journal of the European Society for Organ Transplantation 20110101

• Efficacy of atovaquone and azithromycin or imidocarb dipropionate in cats with acute cytauxzoonosis.

  Journal of veterinary internal medicine 20110101

• A potential interaction between warfarin and atovaquone.

  The Annals of pharmacotherapy 20110101

• Parasitostatic effect of maslinic acid. I. Growth arrest of Plasmodium falciparum intraerythrocytic stages.

  Malaria journal 20110101

• Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.

  Malaria journal 20110101

• Pneumocystis carinii pneumonia prophylaxis: current therapies and recommendations.

  Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses 20110101

• Resolution of a proteinuric nephropathy associated with Babesia gibsoni infection in a dog.

  Journal of the American Animal Hospital Association 20110101

• Mitochondrial electron transport inhibition and viability of intraerythrocytic Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20101201

• Antimalarial drugs: modes of action and mechanisms of parasite resistance.

  Future microbiology 20101201

• Combination of chiroptical, absorption and fluorescence spectroscopic methods reveals multiple, hydrophobicity-driven human serum albumin binding of the antimalarial atovaquone and related hydroxynaphthoquinone compounds.

  Organic & biomolecular chemistry 20101107

• Protoporphyrinogen IX oxidase from Plasmodium falciparum is anaerobic and is localized to the mitochondrion.

  Molecular and biochemical parasitology 20101101

• Acute disseminated fatal toxoplasmosis after haploidentical stem cell transplantation despite atovaquone prophylaxis in a young man.

  The Pediatric infectious disease journal 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.

  Bioorganic & medicinal chemistry 20101101

• Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.

  Journal of medicinal chemistry 20101014

• Computer-assisted design of pro-drugs for antimalarial atovaquone.

  Chemical biology & drug design 20101001

• Spiroindolones, a potent compound class for the treatment of malaria.

  Science (New York, N.Y.) 20100903

• Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.

  Antimicrobial agents and chemotherapy 20100901

• Babesiosis in a patient on infliximab for Crohn's disease.

  Inflammatory bowel diseases 20100801

• Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?

  Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20100801

• Inhibiting Plasmodium cytochrome bc1: a complex issue.

  Current opinion in chemical biology 20100801

• Evaluation and structure-activity relationship study of acute toxicity of naphthoquinones to Photobacterium phosphoreum, Photobacterium T3B.

  Bulletin of environmental contamination and toxicology 20100801

• Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

  AIDS (London, England) 20100515

• LC-APCI mass spectrometric method development and validation for the determination of atovaquone in human plasma.

  Biomedical chromatography : BMC 20100501

• Letter to the editor of travel medicine and infectious disease.

  Travel medicine and infectious disease 20100501

• Chronic malaria infections increase family inequalities and reduce parental fitness: experimental evidence from a wild bird population.

  Journal of evolutionary biology 20100301

• Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100201

• [Effects of combined addition of atovaquone and lithium on the in vitro cell growth of the pathogenic yeast Candida albicans].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20100201

• Congenital babesiosis in a four-week-old female infant.

  The Pediatric infectious disease journal 20100201

• Probing binding determinants in center P of the cytochrome bc(1) complex using novel hydroxy-naphthoquinones.

  Biochimica et biophysica acta 20100101

• Oral atovaquone for the treatment of severe Pneumocystis jirovecii pneumonia in a patient with glucose-6-phosphate dehydrogenase deficiency.

  Scandinavian journal of infectious diseases 20100101

• In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii.

  Antimicrobial agents and chemotherapy 20100101

• Alternatives for malaria prophylaxis during the first trimester of pregnancy: our personal view.

  Journal of travel medicine 20100101

• Rapid identification of chloroquine and atovaquone drug resistance in Plasmodium falciparum using high-resolution melt polymerase chain reaction.

  Malaria journal 20100101

• Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.

  Malaria journal 20100101

• Assessment of adherence to atovaquone-proguanil prophylaxis in travelers.

  Journal of travel medicine 20100101

• Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia.

  Malaria journal 20100101

• Transfusion-associated babesiosis in a 7-month-old infant after bidirectional Glenn procedure.

  Congenital heart disease 20100101

• Babesiosis in the immediate postoperative period after splenectomy for trauma.

  Surgical infections 20091201

• Synthesis and antimalarial activity of new atovaquone derivatives.

  European journal of medicinal chemistry 20091101

• Effectiveness of malaria chemoprophylaxis against Plasmodium falciparum infection in UK travellers: retrospective observational data.

  Travel medicine and infectious disease 20091101

• Mefloquine has more adverse effects than other drugs for malaria prophylaxis.

  BMJ (Clinical research ed.) 20091013

• Drugs for preventing malaria in travellers.

  The Cochrane database of systematic reviews 20091007

• Plasmodium relictum (lineage P-SGS1): Further observation of effects on experimentally infected passeriform birds, with remarks on treatment with Malarone.

  Experimental parasitology 20091001

• Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090915

• Atovaquone derivatives as potent cytotoxic and apoptosis inducing agents.

  Bioorganic & medicinal chemistry letters 20090901

• Design, synthesis and structure-activity relationships of (1H-pyridin-4-ylidene)amines as potential antimalarials.

  Bioorganic & medicinal chemistry letters 20090701

• Atovaquone + proguanil: new indication. For children weighing as little as 5 kg; an inconvenient form. A flavoured syrup would be better suited to infants and young children.

  Prescrire international 20090601

• The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis.

  Journal of drug targeting 20090501

• Importance of using highly pure internal standards for successful liquid chromatography/tandem mass spectrometric bioanalytical assays.

  Rapid communications in mass spectrometry : RCM 20090501

• Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient.

  Transplant infectious disease : an official journal of the Transplantation Society 20090401

• Diterpene formamides from the tropical marine sponge Cymbastela hooperi and their antimalarial activity in vitro.

  Journal of natural products 20090327

• 79-year-old man with fever, malaise, and jaundice.

  Mayo Clinic proceedings 20090301

• Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.

  Bioorganic & medicinal chemistry letters 20090201

• Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study.

  Journal of travel medicine 20090101

• [Mutations of drug target molecules in Pneumocystis jirovecii isolates and future investigations].

  Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology 20090101

• Possible emergence of drug-resistant variants of Babesia gibsoni in clinical cases treated with atovaquone and azithromycin.

  Journal of veterinary internal medicine 20090101

• Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation.

  Pediatric transplantation 20081201

• Well-tolerated chemoprophylaxis uniformly prevented Swedish soldiers from Plasmodium falciparum malaria in Liberia, 2004-2006.

  Military medicine 20081201

• Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review.

  Clinical therapeutics 20081101

• Comparative genomics of the neglected human malaria parasite Plasmodium vivax.

  Nature 20081009

• Splenic pneumocystosis: an atypical presentation of extrapulmonary Pneumocystis infection.

  The AIDS reader 20081001

• Toxoplasmosis in wallabies (Macropus rufogriseus and Macropus eugenii): blindness, treatment with atovaquone, and isolation of Toxoplasma gondii.

  The Journal of parasitology 20080801

• Bullous erythema multiforme after treatment with Malarone, a combination antimalarial composed of atovaquone and proguanil hydrochloride.

  Tropical doctor 20080701

• Mutation underlying resistance of Plasmodium berghei to atovaquone in the quinone binding domain 2 (Qo(2)) of the cytochrome b gene.

  Parasitology international 20080601

• Atovaquone-proguanil resistance in imported falciparum malaria in a young child.

  The Pediatric infectious disease journal 20080601

• Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.

  Journal of medicinal chemistry 20080508

• A drug-selected Plasmodium falciparum lacking the need for conventional electron transport.

  Molecular and biochemical parasitology 20080501

• Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex.

  Molecular pharmacology 20080501

• Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from Cameroon.

  Travel medicine and infectious disease 20080501

• Artemether + lumefantrine: new drug. An alternative to atovaquone + proguanil.

  Prescrire international 20080401

• Atovaquone-statine 'double-drugs' with high antiplasmodial activity.

  ChemMedChem 20080301

• [Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris].

  Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 20080301

• [Babesiosis in an immunocompromised German patient].

  Medizinische Klinik (Munich, Germany : 1983) 20080215

• Plasmodium falciparum malaria and atovaquone-proguanil treatment failure.

  Emerging infectious diseases 20080201

• Complications of coinfection with Babesia and Lyme disease after splenectomy.

  Journal of the American Board of Family Medicine : JABFM 20080101

• In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand.

  Malaria journal 20080101

• Ototoxicity of artemether/lumefantrine in the treatment of falciparum malaria: a randomized trial.

  Malaria journal 20080101

• Fever of unknown origin (FUO) due to babesiosis in a immunocompetent host.

  Heart & lung : the journal of critical care 20080101

• Trends in antimalarial prescriptions in Australia 2002 to 2005.

  Journal of travel medicine 20080101

• Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.

  Malaria journal 20080101

• HIV: treating Pneumocystis pneumonia (PCP).

  BMJ clinical evidence 20080101

• Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20071215

• Inadequate chemoprophylaxis and the risk of malaria.

  Australian family physician 20071201

• Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision.

  The American journal of tropical medicine and hygiene 20071201

• Selective ambulatory management of Plasmodium falciparum malaria in paediatric refugees.

  Archives of disease in childhood 20071101

• A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria.

  The Journal of antimicrobial chemotherapy 20071101

• Babesia gibsoni: detection during experimental infections and after combined atovaquone and azithromycin therapy.

  Experimental parasitology 20071001

• Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi.

  Trends in parasitology 20071001

• Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation.

  Bioorganic & medicinal chemistry letters 20070915

• Drug-resistant malaria - an insight.

  The FEBS journal 20070901

• Clinical efficacy of antiparasite treatments against intestinal helminths and haematic protozoa in Gallotia caesaris (lizards).

  Experimental parasitology 20070801

• Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment.

  Molecular biology and evolution 20070801

• A non-radiolabeled heme-GSH interaction test for the screening of antimalarial compounds.

  Experimental parasitology 20070701

• First case of human babesiosis in Germany - Clinical presentation and molecular characterisation of the pathogen.

  International journal of medical microbiology : IJMM 20070601

• Growth inhibition of Toxoplasma gondii and Plasmodium falciparum by nanomolar concentrations of 1-hydroxy-2-dodecyl-4(1H)quinolone, a high-affinity inhibitor of alternative (type II) NADH dehydrogenases.

  Antimicrobial agents and chemotherapy 20070401

• Prevention and treatment of congenital toxoplasmosis.

  Expert review of anti-infective therapy 20070401

• Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand.

  The American journal of tropical medicine and hygiene 20070401

• Cerebral malaria in spite of peripheral parasite clearance in a patient treated with atovaquone/proguanil.

  Parasitology research 20070301

• In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models.

  Experimental parasitology 20070301

• Analyses of cytochrome b mutations in Plasmodium falciparum isolates in Thai-Myanmar border.

  Travel medicine and infectious disease 20070301

• Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum.

  Nature 20070301

• Molecular characterisation of Babesia gibsoni infection from a pit-bull terrier pup recently imported into South Africa.

  Journal of the South African Veterinary Association 20070301

• Motor neuron disease recovery associated with IV ceftriaxone and anti-Babesia therapy.

  Acta neurologica Scandinavica 20070201

• Atovaquone and azithromycin treatment for babesiosis in an infant.

  The Pediatric infectious disease journal 20070201

• Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).

  The American journal of tropical medicine and hygiene 20070201

• [New drugs against parasitic diseases].

  La Revue du praticien 20070131

• The traveling farm wife.

  The American journal of medicine 20070101

• The safety and tolerance of atovaquone/proguanil for the long-term prophylaxis of plasmodium falciparum malaria in non-immune travelers and expatriates [corrected].

  Journal of travel medicine 20070101

• A man with tropical travel history, fever, and pulmonary infiltrates.

  Comprehensive therapy 20070101

• Synergistic interaction between atovaquone and retinol in Plasmodium falciparum in vitro.

  Wiener klinische Wochenschrift 20070101

• Synergistic interaction between monodesbutyl-benflumetol and retinol in Plasmodium falciparum.

  Wiener klinische Wochenschrift 20070101

• Relapsing vivax malaria after 6 months of daily atovaquone/proguanil in Afghanistan: the case for expanded use of primaquine as a causal prophylactic.

  Journal of travel medicine 20070101

• Outpatient treatment of malaria in recently arrived African migrants.

  The Medical journal of Australia 20061201

• A randomised, double-blind, placebo-controlled trial of atovaquone-proguanil vs. sulphadoxine-pyrimethamine in the treatment of malarial anaemia in Zambian children.

  Tropical medicine & international health : TM & IH 20061101

• Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates imported from Africa, and implications for atovaquone resistance.

  Transactions of the Royal Society of Tropical Medicine and Hygiene 20061001

• Babesiosis masquerading as recurrent immune thrombocytopenic purpura in a splenectomized patient.

  Annals of hematology 20061001

• Plasmodium falciparum malaria associated with mefloquine failure in Gambia.

  Pharmacotherapy 20061001

• Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20061001

• Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations.

  Microbes and infection 20060901

• Randomized, double-blind, placebo-controlled study of Malarone for malaria prophylaxis in non-immune Colombian soldiers.

  The American journal of tropical medicine and hygiene 20060901

• Examination of the impact of a range of Pluronic surfactants on the in-vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone.

  The Journal of pharmacy and pharmacology 20060601

• Folic acid treatment of Zambian children with moderate to severe malaria anemia.

  The American journal of tropical medicine and hygiene 20060601

• Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient.

  Ocular immunology and inflammation 20060601

• Pneumocystis pneumonia in people with HIV.

  Clinical evidence 20060601

• Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria.

  European journal of clinical pharmacology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Drug-induced death of the asexual blood stages of Plasmodium falciparum occurs without typical signs of apoptosis.

  Microbes and infection 20060501

• Molecular basis of Toxoplasma gondii atovaquone resistance modeled in Saccharomyces cerevisiae.

  Molecular and biochemical parasitology 20060401

• Short report: cloning of the Babesia gibsoni cytochrome B gene and isolation of three single nucleotide polymorphisms from parasites present after atovaquone treatment.

  The American journal of tropical medicine and hygiene 20060401

• [Malaria: a medical and economic problem].

  Presse medicale (Paris, France : 1983) 20060401

• Multiple synergistic interactions between atovaquone and antifolates against Plasmodium falciparum in vitro: a rational basis for combination therapy.

  Acta tropica 20060301

• Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.

  The Journal of antimicrobial chemotherapy 20060101

• Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola.

  Malaria journal 20060101

• Atovaquone plus cholestyramine in patients coinfected with Babesia microti and Borrelia burgdorferi refractory to other treatment.

  Advances in therapy 20060101

• Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa.

  Malaria journal 20060101

• Tertian malaria (Plasmodium vivax and Plasmodium ovale) in two travelers despite atovaquone-proguanil prophylaxis.

  Journal of travel medicine 20060101

• Molecular surveillance of mutations in the cytochrome b gene of Plasmodium falciparum in Gabon and Ethiopia.

  Malaria journal 20060101

• Pharmacodynamic interaction between atovaquone and other antimalarial compounds against Plasmodium falciparum in vitro.

  Wiener klinische Wochenschrift 20060101

• Atovaquone/proguanil for the prophylaxis and treatment of malaria.

  Expert review of anti-infective therapy 20051201

• Malaria: prevention in travellers.

  Clinical evidence 20051201

• Plasmodium falciparum: interaction of shikimate analogues with antimalarial drugs.

  Experimental parasitology 20051101

• [Ineffective change of antimalaria prophylaxis to Artemisia vulgaris in a group travelling to West Africa].

  Ugeskrift for laeger 20051024

• Atovaquone-proguanil for treating uncomplicated malaria.

  The Cochrane database of systematic reviews 20051019

• [Malaria chemoprophylaxis].

  Ugeskrift for laeger 20051017

• [Malaria prophylaxis for long-term travellers and expatriates].

  Ugeskrift for laeger 20051017

• The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

  European journal of clinical pharmacology 20050901

• A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy.

  The Journal of infectious diseases 20050901

• Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20050801

• Ubiquinone synthesis in mitochondrial and microsomal subcellular fractions of Pneumocystis spp.: differential sensitivities to atovaquone.

  Eukaryotic cell 20050801

• Short report: no evidence of cardiotoxicity of atovaquone-proguanil alone or in combination with artesunate.

  The American journal of tropical medicine and hygiene 20050801

• Effectiveness of antimalarial drugs.

  The New England journal of medicine 20050728

• Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system.

  The Journal of biological chemistry 20050722

• Occult Plasmodium vivax infection diagnosed by a polymerase chain reaction-based detection system: a case report.

  The American journal of tropical medicine and hygiene 20050701

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.

  Parasite (Paris, France) 20050601

• Pneumocystis pneumonia in people with HIV.

  Clinical evidence 20050601

• Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.

  Journal of medicinal chemistry 20050505

• Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae.

  The Journal of biological chemistry 20050429

• UDP-glucuronosyltransferases and clinical drug-drug interactions.

  Pharmacology & therapeutics 20050401

• Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa.

  The American journal of tropical medicine and hygiene 20050401

• Multiple cytochrome B mutations may cause atovaquone resistance.

  The Journal of infectious diseases 20050301

• Pharmacodynamic interactions of amodiaquine and its major metabolite desethylamodiaquine with artemisinin, quinine and atovaquone in Plasmodium falciparum in vitro.

  Acta tropica 20050301

• A randomized open label clinical trial to compare the efficacy and safety of intravenous quinine followed by oral malarone vs. intravenous quinine followed by oral quinine in the treatment of severe malaria.

  Journal of tropical pediatrics 20050201

• A malaria outbreak following a British military deployment to Sierra Leone.

  The Journal of infection 20050201

• In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil.

  Transactions of the Royal Society of Tropical Medicine and Hygiene 20050101

• Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101

• Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.

  Microbes and infection 20050101

• Simultaneous quantitation of the highly lipophilic atovaquone and hydrophilic strong basic proguanil and its metabolites using a new mixed-mode SPE approach and steep-gradient LC.

  Journal of chromatographic science 20050101

• Malaria prophylaxis for aircrew: safety of atovaquone/proguanil in healthy volunteers under aircraft cabin pressure conditions.

  Journal of travel medicine 20050101

• Acute hepatitis and atovaquone/proguanil.

  Journal of travel medicine 20050101

• 2-Phenyl-beta-lapachone can affect mitochondrial function by redox cycling mediated oxidation.

  Archives of biochemistry and biophysics 20041215

• Malaria: prevention in travellers.

  Clinical evidence 20041201

• Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe.

  The Journal of infectious diseases 20041101

• [New aspects of epidemiology and treatment of Pneumocystis carinii infection].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20041101

• Efficacy of atovaquone against Babesia gibsoni in vivo and in vitro.

  Veterinary parasitology 20040920

• Quinine-resistant severe falciparum malaria effectively treated with atovaquone and proguanil hydrochloride combination therapy.

  Internal medicine (Tokyo, Japan) 20040701

• [Malaria: prophylaxis, treatment, stand-by medication. A single mosquito bite suffices].

  MMW Fortschritte der Medizin 20040617

• Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040615

• Combined effect of atovaquone and pyrrolidine dithiocarbamate in the treatment of acute murine toxoplasmosis.

  Chemotherapy 20040601

• Pneumocystis carinii pneumonia treatment in people infected with HIV.

  Clinical evidence 20040601

• Malaria: prevention in travellers.

  Clinical evidence 20040601

• Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040415

• Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain.

  Protein science : a publication of the Protein Society 20040401

• NADH-ubiquinone oxidoreductase activity in the kinetoplasts of the plant trypanosomatid Phytomonas serpens.

  Parasitology research 20040301

• Short communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana.

  Tropical medicine & international health : TM & IH 20040301

• A malaria outbreak following a British military deployment to Sierra Leone.

  The Journal of infection 20040201

• CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam.

  Tropical medicine & international health : TM & IH 20040201

• Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae.

  The Journal of biological chemistry 20040123

• Malarone treatment failure not associated with previously described mutations in the cytochrome b gene.

  Malaria journal 20040101

• Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesia gibsoni (Asian genotype) infections in dogs.

  Journal of veterinary internal medicine 20040101

• Atovaquone-proguanil (malarone): an effective treatment for uncomplicated Plasmodium falciparum malaria in travelers from Denmark.

  Journal of travel medicine 20040101

• Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031201

• Military aviators, special operations forces, and causal malaria prophylaxis.

  Military medicine 20031201

• HIV: prevention of opportunistic infections.

  Clinical evidence 20031201

• Malaria: prevention in travellers.

  Clinical evidence 20031201

• Diagnosis and treatment of malaria in children.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031115

• New antimalarial drugs.

  Angewandte Chemie (International ed. in English) 20031110

• The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.

  European journal of clinical pharmacology 20031001

• Atovaquone-proguanil for prophylaxis and treatment of malaria.

  The Annals of pharmacotherapy 20030901

• Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam.

  Annals of tropical medicine and parasitology 20030901

• Malaria and children: the risks, precautions, and the nurse's role.

  Professional nurse (London, England) 20030901

• Molecular basis for atovaquone binding to the cytochrome bc1 complex.

  The Journal of biological chemistry 20030815

• Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030801

• Reinstituting trimethoprim--sulfamethoxazole in patients receiving atovaquone for Pneumocystis carinii pneumonia prophylaxis.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030801

• Molecular epidemiology of malaria in Cameroon. XVII. Baseline monitoring of atovaquone-resistant Plasmodium falciparum by in vitro drug assays and cytochrome b gene sequence analysis.

  The American journal of tropical medicine and hygiene 20030801

• Stevens-Johnson syndrome associated with Malarone antimalarial prophylaxis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030701

• The impact of Malarone and primaquine on psychomotor performance.

  Aviation, space, and environmental medicine 20030701

• HIV: opportunistic infections.

  Clinical evidence 20030601

• Atovaquone/proguanil: the need for family protection.

  Journal of travel medicine 20030501

• The safety of atovaquone/proguanil in long-term malaria prophylaxis of nonimmune adults.

  Journal of travel medicine 20030501

• Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries.

  Journal of travel medicine 20030501

• Toxicity related to chloroquine treatment of resistant vivax malaria.

  The Annals of pharmacotherapy 20030401

• The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria.

  Fundamental & clinical pharmacology 20030401

• Problems in prescribing malaria chemoprophylaxis for travelers.

  Fundamental & clinical pharmacology 20030401

• Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis.

  Annals of tropical medicine and parasitology 20030401

• Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports.

  BMJ (Clinical research ed.) 20030322

• [Three newly registered drugs in the Netherlands for the treatment and chemoprophylaxis of malaria: atovaquone-proguanil, artemether-lumefantrine and artemotil].

  Nederlands tijdschrift voor geneeskunde 20030215

• Atovaquone-loaded nanocapsules: influence of the nature of the polymer on their in vitro characteristics.

  International journal of pharmaceutics 20030102

• Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro.

  The American journal of tropical medicine and hygiene 20030101

• Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.

  Drugs 20030101

• Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker.

  Malaria journal 20030101

• The efficacy of chemoprophylaxis against malaria with chloroquine plus proguanil, mefloquine, and atovaquone plus proguanil in travelers from Denmark.

  Journal of travel medicine 20030101

• Current status and replies to frequently posed questions on atovaquone plus proguanil (Malarone) for the prevention of malaria.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20030101

• Detection of atovaquone and Malarone resistance conferring mutations in Plasmodium falciparum cytochrome b gene (cytb).

  Molecular and cellular probes 20030101

• Plasmodium falciparum outwits Malarone, protector of travellers.

  Bulletin of the World Health Organization 20030101

• Plasmodium vivax malaria in spite of atovaquone/proguanil (malarone) prophylaxis.

  Journal of travel medicine 20030101

• Atovaquone/proguanil resistance in Africa: a case report.

  Scandinavian journal of infectious diseases 20030101

• Pharmacodynamic interactions among atovaquone, proguanil and cycloguanil against Plasmodium falciparum in vitro.

  Transactions of the Royal Society of Tropical Medicine and Hygiene 20030101

• Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report.

  Transactions of the Royal Society of Tropical Medicine and Hygiene 20030101

• Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021215

• Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.

  The Journal of antimicrobial chemotherapy 20021201

• Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021115

• Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021101

• Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021001

• [Preventive vaccination for travel. Every dog has it, but only every 10th grandmother].

  MMW Fortschritte der Medizin 20020919

• [Blackwater fever].

  Presse medicale (Paris, France : 1983) 20020907

• Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events.

  Clinical pharmacology and therapeutics 20020901

• [Value of malarone in therapy of malaria tropica].

  Medizinische Klinik (Munich, Germany : 1983) 20020815

• Babesiosis in humans: a treatment review.

  Expert opinion on pharmacotherapy 20020801

• Atovaquone/proguanil for plasmodium falciparum malaria.

  The Pediatric infectious disease journal 20020801

• [New strategies in therapy to roll back malaria].

  Deutsche medizinische Wochenschrift (1946) 20020726

• Characterisation of atovaquone resistance in Leishmania infantum promastigotes.

  International journal for parasitology 20020701

• Determination of atovaquone in tablets by differential pulse polarography.

  Die Pharmazie 20020701

• Zoonotic babesiosis.

  International journal of medical microbiology : IJMM 20020601

• Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020501

• Tolerability of antimalaria drugs.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020501

• Genetic analysis of tachyzoite to bradyzoite differentiation mutants in Toxoplasma gondii reveals a hierarchy of gene induction.

  Molecular microbiology 20020501

• Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.

  Archives of internal medicine 20020422

• Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis.

  European journal of clinical pharmacology 20020401

• Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation.

  European journal of clinical pharmacology 20020401

• [Malarone: a new antimalarial for malaria chemoprevention].

  Medecine tropicale : revue du Corps de sante colonial 20020101

• Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria.

  Malaria journal 20020101

• [Mechanism of action of antimalarials. Value of combined atovaquone/proguanil].

  Medecine tropicale : revue du Corps de sante colonial 20020101

• [Clinical studies using the combination atovaquone-proguanil as malaria prophylaxis in non-immune adult and child travelers].

  Medecine tropicale : revue du Corps de sante colonial 20020101

• [Experience with the combination atovaquone-proguanil in the treatment of uncomplicated Plasmodium falciparum malaria--report of 112 cases].

  Medecine tropicale : revue du Corps de sante colonial 20020101

• [What is the value of the combination atovaquone-proguanil for the clinician?].

  Medecine tropicale : revue du Corps de sante colonial 20020101

• Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011215

• Time of treatment influences the appearance of drug-resistant parasites in Plasmodium falciparum infections.

  Parasitology 20011201

• Current drugs for antimalarial chemoprophylaxis: a review of efficacy and safety.

  Journal of travel medicine 20011201

• New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia.

  JAMA 20011121

• Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011001

• What's new: newly approved drugs for children.

  Pediatrics in review 20011001

• [symbol: see text] Atovaquone + proguanil for malaria prophylaxis.

  Drug and therapeutics bulletin 20011001

• Malaria remains a military medical problem.

  Journal of the Royal Army Medical Corps 20011001

• Are cytochrome b gene mutations the only cause of atovaquone resistance in Pneumocystis?

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20011001

• [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer].

  Klinische Padiatrie 20010901

• Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20010801

• Plasmodium falciparum: the effects of atovaquone resistance on respiration.

  Experimental parasitology 20010801

• Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010715

• Automated solid-phase extraction method for the determination of atovaquone in capillary blood applied onto sampling paper by rapid high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010715

• [Expanded arsenal for prevention and therapy. What is the value of the new malaria drugs? (interview by Waltraut Paukstadt)].

  MMW Fortschritte der Medizin 20010705

• Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.

  Antimicrobial agents and chemotherapy 20010601

• A political analysis of corporate drug donations: the example of Malarone in Kenya.

  Health policy and planning 20010601

• Microbial drug resistance and the roles of the new antibiotics.

  Cleveland Clinic journal of medicine 20010601

• [Malaria--chemoprophylaxis 2001].

  Therapeutische Umschau. Revue therapeutique 20010601

• The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia.

  Cancer chemotherapy and pharmacology 20010601

• Efficacy of atovaquone-proguanil?

  Lancet (London, England) 20010421

• Atovaquone and proguani hydrochloride compared with chloroquine or pyrimethamine/sulfodaxine for treatment of acute Plasmodium falciparum malaria in Peru.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20010401

• The treatment of babesiosis.

  The New England journal of medicine 20010308

• The treatment of babesiosis.

  The New England journal of medicine 20010308

• Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS.

  The Journal of infectious diseases 20010301

• Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration.

  Pharmaceutical research 20010301

• Quantifying and documenting prior beliefs in clinical trials.

  Statistics in medicine 20010227

• In vitro quantitative analysis of (3)H-uracil incorporation by Sarcocytis neurona to determine efficacy of anti-protozoal agents.

  Veterinary parasitology 20010226

• Structure-activity relationships of novel anti-malarial agents. Part 2: cinnamic acid derivatives.

  Bioorganic & medicinal chemistry letters 20010212

• Mode of action and mechanisms of resistance for antimalarial drugs.

  Pharmacology & therapeutics 20010201

• Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients.

  AIDS (London, England) 20010126

• Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.

  Drug metabolism and disposition: the biological fate of chemicals 20010101

• Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model.

  Transactions of the Royal Society of Tropical Medicine and Hygiene 20010101

• The interaction of atovaquone with the P. carinii cytochrome bc1 complex.

  The Journal of eukaryotic microbiology 20010101

• Pneumocystis carinii synthesizes four ubiquinone homologs: inhibition by atovaquone and bupravaquone but not by stigmatellin.

  The Journal of eukaryotic microbiology 20010101

• Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.

  Lancet (London, England) 20001202

• Atovaquone and azithromycin for the treatment of babesiosis.

  The New England journal of medicine 20001116

• Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.

  Veterinary research communications 20000401

• Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.

  Antimicrobial agents and chemotherapy 20000301

• Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.

  Chemico-biological interactions 20000103

• Effects of atovaquone and diospyrin-based drugs on ubiquinone biosynthesis in Pneumocystis carinii organisms.

  Antimicrobial agents and chemotherapy 20000101

• Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.

  Antimicrobial agents and chemotherapy 19990901

• Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.

  The Journal of infectious diseases 19990801

• Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites.

  Molecular microbiology 19990801

• A mechanism for the synergistic antimalarial action of atovaquone and proguanil.

  Antimicrobial agents and chemotherapy 19990601

• Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.

  The Journal of antimicrobial chemotherapy 19981101

• Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia.

  The Journal of infectious diseases 19980401

• Chronic infection with Toxoplasma gondii does not prevent acute disease or colonization of the brain with tissue cysts following reinfection with different strains of the parasite.

  The Journal of parasitology 19970601

• Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.

  Antimicrobial agents and chemotherapy 19970501

• Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite.

  The Journal of biological chemistry 19970214

• Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies.

  Antimicrobial agents and chemotherapy 19970201

• Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.

  Antimicrobial agents and chemotherapy 19970201

• Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis.

  Antimicrobial agents and chemotherapy 19970101

• Efficacy of lasalocid against murine Pneumocystis carinii pneumonitis.

  Antimicrobial agents and chemotherapy 19970101

• In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.

  Antimicrobial agents and chemotherapy 19960901

• In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.

  The Journal of antimicrobial chemotherapy 19960901

• Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19960501

• Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.

  The American journal of tropical medicine and hygiene 19960101

• Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.

  Current topics in microbiology and immunology 19960101

• Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model.

  The Journal of eukaryotic microbiology 19960101

• Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii.

  Antimicrobial agents and chemotherapy 19951201

• New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.

  Journal of medicinal chemistry 19951124

• Acute severe autonomic insufficiency during pentamidine therapy.

  Southern medical journal 19951001

• Antipneumocystis activity of 17C91, a prodrug of atovaquone.

  Antimicrobial agents and chemotherapy 19951001

• Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro.

  Experimental parasitology 19950501

• Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.

  Antimicrobial agents and chemotherapy 19950401

• Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase.

  Antimicrobial agents and chemotherapy 19950201

• In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.

  Antimicrobial agents and chemotherapy 19941001

• Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model.

  The Journal of infectious diseases 19941001

• Rifabutin is active in murine models of toxoplasmosis.

  Antimicrobial agents and chemotherapy 19940301

• Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate.

  The Journal of parasitology 19930801

• Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.

  The New England journal of medicine 19930527

• Structural features of Plasmodium cytochrome b that may underlie susceptibility to 8-aminoquinolines and hydroxynaphthoquinones.

  Molecular and biochemical parasitology 19930301

• The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.

  The Journal of infectious diseases 19930201

• In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.

  Antimicrobial agents and chemotherapy 19920201

• Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.

  The Journal of infectious diseases 19910701

• Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.

  Antimicrobial agents and chemotherapy 19910201

• 566C80, an antimalarial hydroxynaphthoquinone with broad spectrum: experimental activity against opportunistic parasitic infections of AIDS patients.

  The Journal of protozoology 19910101

• Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.

  Antimicrobial agents and chemotherapy 19900201